Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

brentuximab

- PMLiVE

Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

- PMLiVE

Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

Around 800 people in the UK are diagnosed with late-stage disease every year

- PMLiVE

Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn

The companies will aim to discover new antibody-based therapeutics for cancer

- PMLiVE

Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma

Up to 70% of patients with this form of non-Hodgkin lymphoma are diagnosed with advanced disease

- PMLiVE

Innovative Trials Announces New Charity Partnerships

Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

Innovative Trials

- PMLiVE

Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership

The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn

tijana being interviewed

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

Genesis Research Group

- PMLiVE

Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

- PMLiVE

New technique enables study of immune response to cancer using archived tissue samples

FUME-TCRseq was shown to successfully read formalin-fixed paraffin-embedded tissue samples

- PMLiVE

Pfizer’s Adcetris combination shows promise in phase 3 large B-cell lymphoma study

The aggressive blood cancer affects more than 25,000 people in the US every year

- PMLiVE

Gilead and Merus announce oncology partnership worth over $1.5bn

The companies will aim to discover dual tumour-associated antigens targeting trispecific antibodies

- PMLiVE

Researchers develop screening tool to investigate mechanisms behind multiple diseases

The technique will assess genetic changes in cells behind cancer, autoimmunity and neurodegeneration

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links